D. Ross Camidge, MD, PhD, comments on the unmet needs in the management of unresectable locally advanced non–small cell lung cancer and the rationale supporting the role of immunotherapy after chemoradiation therapy in this setting.
For more resources and information regarding anticancer targeted therapies: [ Ссылка ]
